Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.
Hu X, Zhang Q, Sun T, Xiong H, Li W, Teng Y, Lu YS, Tseng LM, Yan M, Li H, Pang D, -Chen SC, Chen W, Jiang O, Wang J, Wu X, Wang X, Zang A, Wang X, Collins JM, Fan E, Jiang L, Zeng X, Turner NC.
Hu X, et al. Among authors: lu ys.
Nat Commun. 2025 May 9;16(1):4324. doi: 10.1038/s41467-025-59210-6.
Nat Commun. 2025.
PMID: 40346047
Free PMC article.
Clinical Trial.